Plus   Neg

Merck To Acquire Tilos Therapeutics In Up To $773 Mln Deal - Quick Facts

Biopharmaceutical company Merck (MRK), known as MSD outside the U.S. and Canada, agreed Monday to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFß complex for the treatment of cancer, fibrosis and autoimmune diseases.

Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGFß by binding to latency-associated peptide, with potential applications across a range of disease indications

TGFß is a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases.

Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Tilos for total potential consideration of up to $773 million, including an upfront payment as well as contingent milestone payments.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT